$HYPD Cashflow Statement | Understand Stock

$HYPD

$2.99 +$0.14 (4.91%) Close

$HYPD Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash Flows From Operating Activities
Net loss
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
Stock-based compensation
Change in fair value of equity consideration payable
Depreciation of property and equipment
Write-off of property and equipment
Gain on forgiveness of PPP 7(a) Loan
Amortization of debt discount
Asset impairments
Write-down of inventories to net realizable value
Provision for clinical supplies to be returned
Provision for returned clinical supplies
Non-cash rent expense
Expense reimbursement
Gain on disposal of property and equipment
Reacquisition of license rights
Non-cash lease expense
Gain on extinguishment of liabilities
Non-cash realized gain - digital assets
Unrealized loss - digital assets
Impairment loss - digital assets
Staking income
Non-cash commission paid to co-validators
Provision for credit losses
Unamortized non-refundable upfront fee on digital asset receivable
Paid-in-kind interest expense
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Deferred license costs
Inventories
License fee and expense reimbursement receivables
Deferred clinical supply costs
Security and equipment deposits
Accounts payable
Accrued compensation
Accrued expenses and other current liabilities
Deferred license fee
Deferred rent
Lease liabilities

Net Cash and Cash Equivalents Used In Operating Activities
Cash Flows From Investing Activities
Purchase of property and equipment
Vendor deposits for property and equipment
Investment in intangible asset
Purchase of productive digital assets
Net Cash and Cash Equivalents Used In Investing Activities

Cash Flows From Financing Activities
Proceeds from sale of common stock and warrants in private placement [1]
Proceeds from sale of common stock in public offering [2]
Proceeds from sale of common stock and warrants in offerings
Payment of offering issuance costs
Payment of offerings issuance costs
Proceeds from sale of common stock in At the Market Program
Payment of issuance costs for At the Market Program
Proceeds from exercise of stock options
Proceeds from sale of common stock and warrants in direct offering
Proceeds from sale of preferred stock and warrants in private placement
Payment of private placement issuance costs
Proceeds from sale of common stock in At the Market offering
Payment of issuance costs for At the Market offering
Proceeds from exercise of stock warrants
Proceeds from PPP 7(a) loan
Proceeds from SVB loan
Proceeds from note payable and equity issued to Avenue
Payment of issuance costs for equity issued to Avenue
Payment of issuance costs for notes issued to Avenue
Proceeds from induced exercise of stock warrants
Payment of cash issuance costs for induced exercise of stock warrants
Reverse stock split settlement of fractional shares
Repayments of notes payable
Payment of preferred dividend
Payment of costs in connection with debt extinguishment
Net Cash and Cash Equivalents Provided By Financing Activities

Net Increase (Decrease) in Cash and Cash Equivalents
Cash and Cash Equivalents - Beginning of Year
Cash and Cash Equivalents - End of Year
Cash and cash equivalents
Restricted cash
Supplemental Disclosure of Cash Flow Information:
Interest
Taxes
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Recognition of right-of-use asset for lease liability upon adoption of ASU 2016-02
Right-of-use assets and lease liabilities recognized upon lease renewal
Shares withheld from option exercise for employee tax liability
Warrants issued for debt issuance costs
Vendor deposits applied to purchases of property and equipment
Original issue discount on notes payable
Warrant modification - incremental value
Deposits of HYPE into liquid staking activities
Redemption of liquid staking tokens for HYPE
Transfer of HYPE to digital asset receivable
Accrued dividend payable
Purchase of insurance policy financed by note payable
Accrual for intangible asset milestone obligation
Reclassification of deferred clinical supply costs to inventories
Modification date carrying value of extinguished Avenue Loan
Modification date fair value of modified Avenue Loan
Warrants issued for debt modification
Warrant modification and additional warrants - incremental value
Common stock issued in consideration for equipment received in conjunction with licensing agreement
Conversion of Avenue Loan to common stock
Common stock issued in consideration for licensing agreement
Cashless exercise of stock options
Common shares issued recorded as debt discount for Avenue Loan
Common stock issued as consideration for reacquisition of licensing agreement
Common stock issued in consideration for reacquisition of licensing agreement
Common stock issued as consideration for modification of loan agreement
Interest expense added to note principal
Issuance of common stock related to vested restricted stock units
Treasury stock held for employee payroll taxes upon the delivery of restricted stock units

Comments